{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["TNF\u03b1 inhibitors", "adalimumab", "etanercept", "infliximab", "plasma cytokines", "psoriasis"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38999459", "DateRevised": {"Year": "2024", "Month": "07", "Day": "15"}, "Article": {"Language": ["eng"], "ELocationID": ["3895", "10.3390/jcm13133895"], "ArticleDate": [{"Year": "2024", "Month": "07", "Day": "02"}], "Journal": {"ISSN": "2077-0383", "JournalIssue": {"Volume": "13", "Issue": "13", "PubDate": {"Year": "2024", "Month": "Jul", "Day": "02"}}, "Title": "Journal of clinical medicine", "ISOAbbreviation": "J Clin Med"}, "ArticleTitle": "Plasma Cytokines for the Prediction of the Effectiveness of TNF\u03b1 Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis.", "Abstract": {"AbstractText": ["<b>Background/Objectives:</b> Psoriasis is a chronic, inflammatory, immuno-mediated cutaneous disease characterized by a prominent TNF\u03b1-IL23/IL17 immune axis. In recent years, targeted therapies have become standard practice for managing moderate-to-severe psoriasis and have demonstrated efficacy. At the same time, identifying factors associated with the success or failure of TNF\u03b1 inhibitor therapy remains one of the most difficult aspects in psoriasis treatment. <b>Methods:</b> A clinical, non-randomized study was conducted to evaluate the impact of TNF\u03b1 inhibitors on the plasma cytokine profiles in patients with moderate-to-severe psoriasis vulgaris (ICD-10 code L40.0). The patients were treated with either etanercept, adalimumab, or infliximab for 16 weeks. Plasma cytokine profiles were assessed using a BioPlex200 System. <b>Results:</b> By the 16th week of therapy, a positive treatment response (PASI \u2265 75) was observed in 51 patients (63%), while 30 patients (37%) showed no response (PASI \u2264 50). When using etanercept, a positive effect was observed in 11 patients (41%), in 14 patients (52%) using adalimumab, and in 26 patients (96%) using infliximab. Analysis of the baseline cytokine levels revealed no differences between the \"positive effect\" and \"no effect\" groups, except for IL20, which was 2.61 times higher in the \"positive effect\" group compared to the \"no effect\" group, suggesting its potential predictive role in the effectiveness of therapy with TNF\u03b1 inhibitors. Treatment led to a decrease in IL17F, IL31, sCD40L, and VEGF for all patients, and in IL20 for the \"positive effect\" group. The increase in ICAM1 in the \"no effect\" group suggests the possible retention of active migration and the fixation of T cells in the affected skin in these patients. No significant difference in cytokine levels was observed when categorizing patients into subgroups based on the effectiveness of therapy with etanercept, infliximab, and adalimumab; only a pre- and post-treatment difference in the whole cohort was noted. A random forest model showed the importance of VEGF, sCD40L, and ICAM1. <b>Conclusions:</b> The baseline levels of VEGF, sCD40L, and ICAM1, as well as IL20, could serve as potential predictors of treatment effectiveness using TNFa inhibitors. However, this hypothesis requires confirmation with a larger patient population."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Karamova", "ForeName": "Arfenya", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Znamenskaya", "ForeName": "Ludmila", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Vorontsova", "ForeName": "Anastasiia", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Obraztsova", "ForeName": "Olga", "Initials": "O"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Nikonorov", "ForeName": "Alexandr", "Initials": "A"}, {"Identifier": ["0000-0002-6360-2194"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (VILAR), Moscow 117216, Russia."}], "LastName": "Nikonorova", "ForeName": "Eugenia", "Initials": "E"}, {"Identifier": ["0000-0002-9578-7947"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Deryabin", "ForeName": "Dmitry", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Research Center of Dermatovenereology and Cosmetology, Moscow 107076, Russia."}], "LastName": "Kubanov", "ForeName": "Alexey", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "J Clin Med", "NlmUniqueID": "101606588", "ISSNLinking": "2077-0383"}, "CoiStatement": "The authors declare no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Ten Bergen L.L., Petrovic A., Krogh A., Arebrot A., Appel S. The TNF/IL-23/IL-17 axis\u2014Head-to-head trials comparing different biologics in psoriasis treatment. Scand. J. Immunol. 2020;92:e12946. doi: 10.1111/sji.12946.", "ArticleIdList": ["10.1111/sji.12946", "32697374"]}, {"Citation": "Leone G.M., Mangano K., Petralia M.C., Nicoletti F., Fagone P. Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med. 2023;12:1630. doi: 10.3390/jcm12041630.", "ArticleIdList": ["10.3390/jcm12041630", "PMC9963154", "36836166"]}, {"Citation": "Zakostelska Z.J., Reiss Z., Tlaskalova-Hogenova H., Rob F. Paradoxical Reactions to Anti-TNF\u03b1 and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved? Dermatol. Ther. 2023;13:911\u2013933. doi: 10.1007/s13555-023-00904-4.", "ArticleIdList": ["10.1007/s13555-023-00904-4", "PMC10060503", "36929119"]}, {"Citation": "Warren R.B., Gooderham M., Burge R., Zhu B., Amato D., Liu K.H., Shrom D., Guo J., Brnabic A., Blauvelt A. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J. Am. Acad. Dermatol. 2020;82:1138\u20131149. doi: 10.1016/j.jaad.2019.12.038.", "ArticleIdList": ["10.1016/j.jaad.2019.12.038", "31884091"]}, {"Citation": "Wong U., Cross R.K. Primary and Secondary Nonresponse to Infliximab: Mechanisms and Countermeasures. Expert Opin. Drug Metab. Toxicol. 2017;13:1039\u20131046. doi: 10.1080/17425255.2017.1377180.", "ArticleIdList": ["10.1080/17425255.2017.1377180", "28876147"]}, {"Citation": "Fine S., Papamichael K., Cheifetz A.S. Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol. Hepatol. 2019;15:656\u2013665.", "ArticleIdList": ["PMC6935028", "31892912"]}, {"Citation": "Lauffer F., Eyerich K. Eczematized psoriasis\u2014A frequent but often neglected variant of plaque psoriasis. JDDG J. Dtsch. Dermatol. Ges. 2023;21:445\u2013453. doi: 10.1111/ddg.14991.", "ArticleIdList": ["10.1111/ddg.14991", "36772926"]}, {"Citation": "Bystrom J., Clanchy F.I., Taher T.E., Al-Bogami M.M., Muhammad H.A., Alzabin S., Mangat P., Jawad A.S., Williams R.O., Mageed R.A. Response to Treatment with TNF\u03b1 Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes. Clin. Rev. Allergy Immunol. 2017;53:265\u2013276. doi: 10.1007/s12016-017-8610-y.", "ArticleIdList": ["10.1007/s12016-017-8610-y", "PMC5597702", "28488248"]}, {"Citation": "Magee C., Jethwa H., FitzGerald O.M., Jadon D.R. Biomarkers Predictive of Treatment Response in Psoriasis and Psoriatic Arthritis: A Systematic Review. Ther. Adv. Musculoskelet. Dis. 2021;13:1\u201314. doi: 10.1177/1759720X211014010.", "ArticleIdList": ["10.1177/1759720X211014010", "PMC8111521", "33995606"]}, {"Citation": "Andersen C.S.B., Kvist-Hansen A., Siewertsen M., Enevold C., Hansen P.R., Kaur-Knudsen D., Zachariae C., Nielsen C.H., Loft N., Skov L. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci. 2023;24:6111. doi: 10.3390/ijms24076111.", "ArticleIdList": ["10.3390/ijms24076111", "PMC10094459", "37047086"]}, {"Citation": "Romero I.B., Puchades A.M., Pibernat M.R., Genao D.P.R., Dobao P.d.l.C., Carrascosa J.M. Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: A systematic literature review. Ann. Med. 2023;55:1335\u20131345. doi: 10.1080/07853890.2023.2192957.", "ArticleIdList": ["10.1080/07853890.2023.2192957", "PMC10075489", "37014135"]}, {"Citation": "Verbenko D.A., Karamova A.E., Artamonova O.G., Deryabin D.G., Rakitko A., Chernitsov A., Krasnenko A., Elmuratov A., Solomka V.S., Kubanov A.A. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. J. Pers. Med. 2021;11:20. doi: 10.3390/jpm11010020.", "ArticleIdList": ["10.3390/jpm11010020", "PMC7823747", "33383665"]}, {"Citation": "R Core Team  R Version 4.2.2 (2022\u201310\u201331 ucrt)\u2014\u201dInnocent and Trusting\u201d: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2022.  [(accessed on 18 May 2024)].  Available online:  https://www.R-project.org."}, {"Citation": "Shitikov V.K., Mastitsky S.E. Classification, Regression, Data Mining Algorithms Using R. 2017.  [(accessed on 18 May 2024)].  Available online:  https://github.com/ranalytics/data-mining. (In Russian)"}, {"Citation": "Strobl C., Boulesteix A.-L., Kneib T., Augustin T., Zeileis A. Conditional variable importance for random forests. BMC Bioinform. 2008;9:307. doi: 10.1186/1471-2105-9-307.", "ArticleIdList": ["10.1186/1471-2105-9-307", "PMC2491635", "18620558"]}, {"Citation": "Ling C.X., Huang J., Zhang H. Advances in Artificial Intelligence, Proceedings of the 16th Conference of the Canadian Society for Computational Studies of Intelligence, AI 2003, Halifax, NS, Canada, 11\u201313 June 2003. Springer; Berlin/Heidelberg, Germany: 2003. AUC: A better measure than accuracy in comparing learning algorithms; pp. 329\u2013341."}, {"Citation": "Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin. Arthritis Rheum. 2010;40:233\u2013240. doi: 10.1016/j.semarthrit.2010.04.003.", "ArticleIdList": ["10.1016/j.semarthrit.2010.04.003", "20580412"]}, {"Citation": "Fiorino G., Danese S., Pariente B., Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun. Rev. 2014;13:15\u201319. doi: 10.1016/j.autrev.2013.06.005.", "ArticleIdList": ["10.1016/j.autrev.2013.06.005", "23777821"]}, {"Citation": "Horiuchi T., Mitoma H., Harashima S.-I., Tsukamoto H., Shimoda T. Transmembrane TNF-\u03b1: Structure, Function and Interaction with Anti-TNF Agents. Rheumatology. 2010;49:1215\u20131228. doi: 10.1093/rheumatology/keq031.", "ArticleIdList": ["10.1093/rheumatology/keq031", "PMC2886310", "20194223"]}, {"Citation": "Brownstone N.D., Hong J., Mosca M., Hadeler E., Liao W., Bhutani T., Koo J. Biologic treatments of psoriasis: An update for the clinician. Biol. Targets Ther. 2021;15:39\u201351. doi: 10.2147/BTT.S252578.", "ArticleIdList": ["10.2147/BTT.S252578", "PMC7896737", "33623366"]}, {"Citation": "Archer K.J., Kimes R.V. Empirical characterization of random forest variable importance measures. Comput. Stat. Data Anal. 2008;52:2249\u20132260. doi: 10.1016/j.csda.2007.08.015.", "ArticleIdList": ["10.1016/j.csda.2007.08.015"]}, {"Citation": "Yu L., Tao G., Zhu L., Wang G., Li Z., Ye J., Chen Q. Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis. BMC Cancer. 2019;19:464. doi: 10.1186/s12885-019-5646-9.", "ArticleIdList": ["10.1186/s12885-019-5646-9", "PMC6525347", "31101024"]}, {"Citation": "Lloyd T., Steigler P., Mpande C.A.M., Rozot V., Mosito B., Schreuder C., Reid T.D., Hatherill M., Scriba T.J., Little F., et al. Multidimensional analysis of immune responses identified biomarkers of recent Mycobacterium tuberculosis infection. PLoS Comput. Biol. 2021;17:e1009197. doi: 10.1371/journal.pcbi.1009197.", "ArticleIdList": ["10.1371/journal.pcbi.1009197", "PMC8351927", "34319988"]}, {"Citation": "O\u2019Kell A.L., Garrett T.J., Wasserfall C., Atkinson M.A. Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes. Sci. Rep. 2017;7:9467. doi: 10.1038/s41598-017-09908-5.", "ArticleIdList": ["10.1038/s41598-017-09908-5", "PMC5573354", "28842637"]}, {"Citation": "Pritulo O.A., Petrov A.A., Maraqa M.Y.N. Clinical significance of plasma markers of angiogenesis in patients with psoriasis. Russ. J. Skin Vener. Dis. 2022;25:409\u2013418. doi: 10.17816/dv111100.", "ArticleIdList": ["10.17816/dv111100"]}, {"Citation": "Marina M.E., Roman I.I., Constantin A.M., Mihu C.M., T\u0103taru A.D. VEGF involvement in psoriasis. Clujul Med. 2015;88:247\u2013252. doi: 10.15386/cjmed-494.", "ArticleIdList": ["10.15386/cjmed-494", "PMC4632878", "26609252"]}, {"Citation": "Barton S.P., Abdullah M.S., Marks R. Quantification of microvascular changes in the skin in patients with psoriasis. Br. J. Dermatol. 1992;126:569\u2013574. doi: 10.1111/j.1365-2133.1992.tb00101.x.", "ArticleIdList": ["10.1111/j.1365-2133.1992.tb00101.x", "1610707"]}, {"Citation": "Sudhesan A., Rajappa M., Chandrashekar L., Ananthanarayanan P., Thappa D., Satheesh S., Chandrasekaran A. Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils. Hum. Immunol. 2017;78:657\u2013663. doi: 10.1016/j.humimm.2017.08.004.", "ArticleIdList": ["10.1016/j.humimm.2017.08.004", "28803785"]}, {"Citation": "Bozduman T., Evans S.E., Karahan S., Hayran Y., Akbiyik F., Lay I. Genetic risk factors for psoriasis in Turkish population: -1540 C/A, -1512 Ins18, and +405 C/G polymorphisms within the vascular endothelial growth factor gene. Ann. Dermatol. 2016;28:30\u201339. doi: 10.5021/ad.2016.28.1.30.", "ArticleIdList": ["10.5021/ad.2016.28.1.30", "PMC4737833", "26848216"]}, {"Citation": "Young H.S., Bhushan M., Griffiths C.E., Summers A.M., Brenchley P.E. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J. Investig. Dermatol. 2004;122:209\u2013215. doi: 10.1046/j.0022-202X.2003.22107.x.", "ArticleIdList": ["10.1046/j.0022-202X.2003.22107.x", "14962110"]}, {"Citation": "Luengas-Martinez A., Paus R., Young H.S. A novel personalized treatment approach for psoriasis: Anti-vascular endothelial growth factor-A (VEGF-A) therapy. Br. J. Dermatol. 2022;186:782\u2013791. doi: 10.1111/bjd.20940.", "ArticleIdList": ["10.1111/bjd.20940", "PMC9313866", "34878645"]}, {"Citation": "Campanati A., Goteri G., Simonetti O., Ganzetti G., Giuliodori K., Giuliano A., Sabato S., Stramazzotti D., Gulini E., Dusi D., et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: Videocapillaroscopic, histological and immunohistochemical evaluation. Int. J. Immunopathol. Pharmacol. 2009;22:371\u2013377. doi: 10.1177/039463200902200214.", "ArticleIdList": ["10.1177/039463200902200214", "19505391"]}, {"Citation": "Cordiali-Fei P., Trento E., D\u2019Agosto G., Bordignon V., Mussi A., Ardig\u00f3 M., Mastroianni A., Vento A., Solivetti F., Berardesca E., et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann. N. Y. Acad. Sci. 2007;1110:578\u2013589. doi: 10.1196/annals.1423.062.", "ArticleIdList": ["10.1196/annals.1423.062", "17911474"]}, {"Citation": "Xia Y.-P., Li B., Hylton D., Detmar M., Yancopoulos G.D., Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003;102:161\u2013168. doi: 10.1182/blood-2002-12-3793.", "ArticleIdList": ["10.1182/blood-2002-12-3793", "12649136"]}, {"Citation": "Wen J., Pei H., Wang X., Xie C., Li S., Huang L., Qiu N., Wang W., Cheng X., Chen L. Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation. J. Dermatol. Sci. 2014;74:242\u2013250. doi: 10.1016/j.jdermsci.2014.03.001.", "ArticleIdList": ["10.1016/j.jdermsci.2014.03.001", "24685902"]}, {"Citation": "Venerito V., Natuzzi D., Bizzoca R., Lacarpia N., Cacciapaglia F., Lopalco G., Iannone F. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. Clin. Exp. Immunol. 2020;201:200\u2013204. doi: 10.1111/cei.13451.", "ArticleIdList": ["10.1111/cei.13451", "PMC7366736", "32383167"]}, {"Citation": "Kubanov A.A., Solomka V.S., Karamova A.E., Verbenko D.A., Vasileva E.L., Artamonova O.G. The effect of apremilast therapy on skin cytokine levels in patients with psoriasis. Russ. Open Med. J. 2020;9:310. doi: 10.15275/rusomj.2020.0310.", "ArticleIdList": ["10.15275/rusomj.2020.0310"]}, {"Citation": "Vi\u010di\u0107 M., Ka\u0161telan M., Brajac I., Soto\u0161ek V., Massari L.P. Current Concepts of Psoriasis Immunopathogenesis. Int. J. Mol. Sci. 2021;22:11574. doi: 10.3390/ijms222111574.", "ArticleIdList": ["10.3390/ijms222111574", "PMC8584028", "34769005"]}, {"Citation": "Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M. Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci. 2018;19:179. doi: 10.3390/ijms19010179.", "ArticleIdList": ["10.3390/ijms19010179", "PMC5796128", "29316717"]}, {"Citation": "Wei C.-C., Chen W.-Y., Wang Y.-C., Chen P.-J., Lee J.Y.-Y., Wong T.-W., Chen W.C., Wu J.-C., Chen G.-Y., Chang M.-S., et al. Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. 2005;117:65\u201372. doi: 10.1016/j.clim.2005.06.012.", "ArticleIdList": ["10.1016/j.clim.2005.06.012", "16043414"]}]}], "History": [{"Year": "2024", "Month": "4", "Day": "3"}, {"Year": "2024", "Month": "5", "Day": "8"}, {"Year": "2024", "Month": "5", "Day": "19"}, {"Year": "2024", "Month": "7", "Day": "13", "Hour": "7", "Minute": "44"}, {"Year": "2024", "Month": "7", "Day": "13", "Hour": "7", "Minute": "43"}, {"Year": "2024", "Month": "7", "Day": "13", "Hour": "1", "Minute": "10"}, {"Year": "2024", "Month": "7", "Day": "2"}], "PublicationStatus": "epublish", "ArticleIdList": ["38999459", "PMC11242498", "10.3390/jcm13133895", "jcm13133895"]}}]}